GlySure, an Abingdon, UK-based developer of in-hospital continuous blood glucose monitoring systems, closed its $10.9m Series C financing round.
Backers include Morningside Venture and existing investors Amadeus Capital Partners, Chester Investments and Delta Partners.
This investment brings the total amount raised to date by the company to $19.5m.
GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU). It now intends to use the funding to complete clinical trials to support regulatory approval in the United States and Europe.
Founded in May 2006 and led by CEO Chris Jones, the company recently completed initial human use trials on over 90 intensive care patients.
GlySure currently has 16 employees.